Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 5/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CTNNB1 | P35222 | 5/20 | 0.54 |
| ▸ | WNT3A | P56704 | 4/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL471019 | 0.98 | ALDH1A1 (0.69) | ALDH1A1LMNAKMT2ANPC1RAB9A | |
| SCHEMBL13044823 | 0.88 | LMNA (0.69) | ALDH1A1LMNAKMT2ANPC1RAB9A | |
| SCHEMBL12719803 | 0.86 | LMNA (0.67) | ALDH1A1LMNAKMT2ANPC1RAB9A | |
| SCHEMBL13536701 | 0.85 | ALDH1A1 (0.65) | ALDH1A1LMNAKMT2ANPC1RAB9A | |
| SCHEMBL14139292 | 0.83 | ALDH1A1 (0.62) | ALDH1A1LMNAKMT2ANPC1RAB9A | |
| SCHEMBL14878250 | 0.83 | LMNA (0.62) | ALDH1A1LMNAKMT2ANPC1RAB9A | |
| SCHEMBL5021506 | 0.83 | LMNA (0.62) | ALDH1A1LMNAKMT2ANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL5954117 | 0.83 | LMNA (0.62) | ALDH1A1LMNAKMT2ANPC1RAB9A | |
| SCHEMBL13562555 | 0.82 | LMNA (0.61) | ALDH1A1LMNAKMT2ANPC1RAB9A | |
| SCHEMBL28800151 | 0.82 | ALDH1A1 (0.61) | ALDH1A1LMNAKMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398126-B2 | Process to synthesize 5-(3pyridyl)-2,2′-bithiophene(sensitizer) | FERMENTA BIOTECH LIMITED (IN) | 2025-08-26 | — | — | US | claimed |
| CN-119955874-A | Duloxetine Process for the preparation of intermediates | 南京红杉生物科技有限公司 | 2025-05-09 | — | — | CN | claimed |
| US-20220306615-A1 | AN IMPROVED PROCESS TO SYNTHESIZE 5-(3PYRIDYL)-2,2'-BITHIOPHENE(SENSITIZER) | FERMENTA BIOTECH LIMITED (IN) | 2022-09-29 | — | — | US | claimed |
| CN-114437022-A | Preparation method of duloxetine intermediate | 浙江拓普药业股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-110964703-B | Enzyme for preparing intermediate of antidepressant duloxetine, biocatalysis method and application thereof | 南京朗恩生物科技有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-110964703-A | Enzyme for preparing intermediate of antidepressant duloxetine, biocatalysis method and application thereof | 南京朗恩生物科技有限公司 | 2020-04-07 | — | — | CN | claimed |
| CN-110938609-A | Ketoreductase mutant with enhanced activity and application thereof | 南京朗恩生物科技有限公司 | 2020-03-31 | — | — | CN | claimed |
| CN-110923277-A | Method for preparing S-3-dimethylamino-1- (2-thienyl) -1-propanol by biocatalysis | 南京朗恩生物科技有限公司 | 2020-03-27 | — | — | CN | claimed |
| US-12398126-B2 | Process to synthesize 5-(3pyridyl)-2,2′-bithiophene(sensitizer) | FERMENTA BIOTECH LIMITED (IN) | 2025-08-26 | — | — | US | disclosed |
| CN-119955874-A | Duloxetine Process for the preparation of intermediates | 南京红杉生物科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-114214295-B | Carbonyl reductase and method for synthesizing (S) -3- (dimethylamino) -1- (2-thienyl) -1-propanol | 江苏海洋大学 | 2024-05-03 | — | — | CN | disclosed |
| CN-116640115-A | Preparation method of 3-methylamino-1- (2-thienyl) -1-propanone hydrochloride | 浙江工业大学 | 2023-08-25 | — | — | CN | disclosed |
| US-20220306615-A1 | AN IMPROVED PROCESS TO SYNTHESIZE 5-(3PYRIDYL)-2,2'-BITHIOPHENE(SENSITIZER) | FERMENTA BIOTECH LIMITED (IN) | 2022-09-29 | — | — | US | disclosed |
| CN-114437022-A | Preparation method of duloxetine intermediate | 浙江拓普药业股份有限公司 | 2022-05-06 | — | — | CN | disclosed |
| US-5023269-A | 3-aryloxy-3-substituted propanamines | ELI LILLY AND COMPANY (US) | 1991-06-11 | — | — | US | disclosed |
| EP-0273658-B1 | 3-ARYLOXY-3-SUBSTITUTED PROPANAMINES | ELI LILLY AND COMPANY (US) | 1990-10-31 | — | — | EP | disclosed |
| US-4956388-A | ANTIDEPRESSANTS, ANTIANXIETY, TREATMENT OF OBESITY, ADDICTION TO SMOKING AND ALCOHOL | ELI LILLY AND COMPANY (US) | 1990-09-11 | — | — | US | disclosed |
| EP-0273658-A1 | 3-Aryloxy-3-substituted propanamines | ELI LILLY AND COMPANY (US) | 1988-07-06 | — | — | EP | disclosed |
| EP-0084941-B1 | AMIDE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-03-11 | — | — | EP | disclosed |
| US-4528282-A | Amide derivatives | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1985-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306615-A1 | AN IMPROVED PROCESS TO SYNTHESIZE 5-(3PYRIDYL)-2,2'-BITHIOPHENE(SENSITIZER) | TH, TPST2, TYR | HDAC1 3597/4885ALDH1A1 3645/4885LMNA 4551/4885 |
| US-12398126-B2 | Process to synthesize 5-(3pyridyl)-2,2′-bithiophene(sensitizer) | TPST2, TH, TDO2 | HDAC1 3376/4885ALDH1A1 3314/4885LMNA 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.